TY - JOUR
T1 - Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis
T2 - Experience from a Single Referral Pediatric Intensive Care Unit
AU - Castrejón Vázquez, Maria Isabel
AU - Reséndiz-Albor, Aldo Arturo
AU - Ynga-Durand, Mario A.
AU - Arciniega Martínez, Ivonne Mac Iel
AU - Orellana-Villazon, Vanessa Ivonne
AU - García López, Carlos Alberto
AU - Laue Noguera, Maria Laura
AU - Vargas Camaño, Maria Eugenia
N1 - Publisher Copyright:
© 2019 Maria Isabel Castrejón Vázquez et al.
PY - 2019
Y1 - 2019
N2 - Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.
AB - Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.
UR - http://www.scopus.com/inward/record.url?scp=85068969024&partnerID=8YFLogxK
U2 - 10.1155/2019/8980506
DO - 10.1155/2019/8980506
M3 - Artículo
C2 - 31341910
AN - SCOPUS:85068969024
SN - 2314-6133
VL - 2019
JO - BioMed Research International
JF - BioMed Research International
M1 - 8980506
ER -